Regenerative Medicine Market
PUBLISHED: 2023 ID: SMRC22433
SHARE
SHARE

Regenerative Medicine Market

Regenerative Medicine Market Forecasts to 2028 - Global Analysis By Product (Progenitor and Stem Cell Therapies, Gene Therapies and Other Products), Material (Genetically Engineered Material, Synthetic material and Other Materials), Application (Oncology, Wound Care and Other Applications), End User and Geography

4.8 (34 reviews)
4.8 (34 reviews)
Published: 2023 ID: SMRC22433

This report covers the impact of COVID-19 on this global market
Loading...

Years Covered

2020-2028

Estimated Year Value (2022)

US $35.01 BN

Projected Year Value (2028)

US $73.94 BN

CAGR (2022 - 2028)

13.27%

Regions Covered

North America, Europe, Asia Pacific, South America, and Middle East & Africa

Countries Covered

US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa

Largest Market

North America

Highest Growing Market

Asia Pacific

 

According to Stratistics MRC, the Global Regenerative Medicine Market is accounted for $35.01 billion in 2022 and is expected to reach $73.94 billion by 2028 growing at a CAGR of 13.27% during the forecast period. Regenerative medicine repairs tissue or organs that have been damaged by disease, trauma, or congenital abnormalities, as opposed to the present clinical strategy, which focuses mostly on treating symptoms. The methods used to attain these breakthroughs include tissue engineering, cellular therapy, medical devices, and artificial organs. Regenerative medicine is an exciting field that aims to repair and restore the structure and function of damaged tissues and organs. It also intends to discover cures for permanently injured organs. This approach aims to find a cure for previously incurable illnesses and injuries.

According to the Alliance for Regenerative Medicine (ARM) 2021 report, the global financing in this market was raised to USD 22.7 billion in 2021 from USD 19.9 billion in 2020 to support 2,406 products that are under investigation.



 

Market Dynamics:

Driver:

Increasing investments in R&D activities leading to innovative product launches

Increasing investments in this sector have resulted in full-fledged research and development operations, as various investors support start-up firms focusing on the development of novel cures and products in the market. This has also paved the path for large mergers, research collaborations, and partnerships to profit from R&D operations. Aside from commercial businesses, numerous government and government-funded research organisations are aggressively investing in this industry to develop viable treatment options for a variety of chronic conditions such as cancer, Parkinson's disease, diabetes, renal disorders, cardiovascular diseases, and others.

Restraint:

High treatment costs and inadequate reimbursement policies

The high costs of therapy with these products, as well as a lack of reimbursement rules, are major obstacles limiting market expansion. Due to the lack of coverage provided by the major insurance providers, patients' only options are to pay for treatment out of pocket or through crowd fundraising, which delays treatment and inhibits market growth. Moreover, there are limited approved therapies for a wide range of patient population suffering from various genetic disorders which are considerably expensive and may have other side effects which restrains its adoption, limiting the market growth.

Opportunity:

Strategic acquisitions by key market players

One of the most prevalent worldwide regenerative medicine market trends is the incorporation of strategic acquisitions by key competitors in order to expand their R&D capabilities. This market's goods include a variety of unique techniques developed from living cells and protein, enzymes, antibodies, antibody-drug conjugates (ADC), gene and cellular components that have resulted in life-saving medicines for a variety of chronic diseases. However, there may be a mismatch between aspirations and realities when it comes to putting these technologies into clinical practise. Some significant businesses are focusing on acquisitions to boost their R&D capabilities in order to bridge this gap and develop research in diverse clinical applications.

Threat:

Shortage of skilled professionals

The skills necessary are projected to evolve as regenerative medicine progresses. Regenerative medicine bio manufacturing is rapidly expanding, resulting in a mismatch between the skill sets required by labourers in the workplace and the market's incapacity to fill those positions. Despite significant investment in the cell and gene therapies (CGT) business, producing these medicines has proven difficult due to a dearth of competent individuals. A limited workforce and inadequate understanding involved with manufacturing novel and emerging medicines contribute to the slow commercialization of CGTs.

Covid-19 Impact

The COVID-19 pandemic presented profitable chances for operational players due to the urgent need for the discovery of novel medicines against SARS-COV-2. Several projects are being conducted in the cell and gene therapy manufacturing industry, including the T-cell therapy space. For example, the Duke-NUS medical school's emerging infectious diseases research programme in Singapore demonstrated the usefulness of these immunotherapies in treating patients with COVID-19 infection based on earlier research findings. The availability of many initiatives and ongoing funding by government and corporate entities to assist R&D also accelerates the industry's advancement. Similarly, initiatives adopted by market players to raise finance for the R&D of regenerative medicine support the market progression.

The tissue-engineering segment is expected to be the largest during the forecast period

The tissue-engineering segment is estimated to have a lucrative growth, due to increased demand for its products, such as scaffolds, bio matrixes, and others in wound care. The primary reason for the large share of the tissue-engineering segment is the ability to replace a damaged structure with a totally living structure, as well as the promise for finding remedies for previously untreatable medical problems. Furthermore, significant investment in research & development for generating effective treatments, as well as the continuous introduction of new and successful products, are projected to drive demand in the tissue engineering industry.

The oncology segment is expected to have the highest CAGR during the forecast period

The oncology segment is anticipated to witness the fastest CAGR growth during the forecast period, due to the high incidence of cancer globally and increasing demand for development of new technologies for the treatment of cancer. Factors such as the increased prevalence of cancer have resulted in huge unmet cancer patient population demands, and numerous novel medicines, such as CAR-T cell therapy, have been created to meet this demand. Furthermore, increased active government support through research grants and awareness campaigns is adding to the segment's growth.

Region with highest share:

North America is projected to hold the largest market share during the forecast period owing to the presence of a significant number of key players in the U.S. The presence of advanced technology and research institutes involved in the development of innovative treatments contribute to the high number of clinical trials in this region. The availability of finances, as well as many initiatives by government and private organisations, contributes to the largest revenue flow from the United States.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the expansion of infrastructure and facilities to accelerate stem cell research in the emerging economies of the region. In Japan, the Ministry of Health, Labor, and Welfare passed the Regenerative Medicine Law in April 2013, paving the way for the clinical development of regenerative and cell-based therapies. Similarly, the Chinese government has allowed various human embryonic stem cell research operations, encouraging researchers to investigate the clinical potential of these cells.



 

Key players in the market

Some of the key players profiled in the Regenerative Medicine Market include Smith & Nephew plc, Shenzhen SibionoGeneTech Co., Ltd., AstraZeneca, Aspect Biosystems, Integra LifeSciences Corporation, Novartis AG, Medtronic plc, Amgen, Inc., MiMedx Group, Baxter, Eli Lilly & Co., Mesoblast Ltd., Bayer AG, Corestem, Inc., Bluebird Bio, Inc. and Regrow Biosciences Pvt. Ltd.

Key Developments:

In January 2021, Integra LifeSciences Holdings Corporation completed the acquisition of ACell, Inc. Acquiring ACell and its proprietary MatriStem UBM technologies enabled Integra to provide more comprehensive complex wound management solutions to address patients.

In January 2021, Eli Lilly & Co. acquired Prevail Therapeutics with a deal to establish a gene therapy program at pharma giant anchored by Prevail's Adeno-Associated Virus (AAV)9-based gene therapies for patients with neurodegenerative diseases. The deal broadened their commitment to address fatal genetic forms of neurodegenerative disease through new modalities. This acquisition bought critical technology and highly skilled teams to complement the existing expertise at Lilly.

In November 2020, Novartis collaborated with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of Acute Respiratory Distress Syndrome (ARDS). As a potential first ARDS therapy, remestemcel-L used Mesenchymal Stromal Cells (MSCs), a cell-based platform technology, to treat this deadly condition and improve outcomes. Novartis intended to initiate a Phase III study in non-COVID-19-related ARDS after the anticipated closing of this license agreement.

In October 2020, Bayer acquired Asklepios BioPharmaceutical to broaden the innovation base in cell and gene therapy. This fueled Bayer’s cell and gene therapy platform with potential to bring treatments to patients across multiple disease areas with high unmet need.

In October 2018, Mesoblast Limited expanded its partnership with JCR Pharmaceuticals Co. Ltd. in Japan to the use of mesenchymal stem cells (MSCs) for the treatment of new-borns who lack sufficient blood supply and oxygen to the brain, a condition termed neonatal hypoxic ischemic encephalopathy (HIE).

Products Covered:
• Progenitor and Stem Cell Therapies
• Gene Therapies
• Tissue-Engineering
• Cell Therapies
• Other Products

Materials Covered:
• Genetically Engineered Material
• Synthetic material
• Biologically derived material
• Pharmaceutical

Applications Covered:
• Oncology
• Wound Care
• Cardiovascular
• Musculoskeletal
• Ophthalmology
• Other Applications

End Users Covered:
• Government & Academic Research Institutes
• Hospitals & Clinics
• Commercial Industries

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Regenerative Medicine Market, By Product
5.1 Introduction
5.2 Progenitor and Stem Cell Therapies
5.3 Gene Therapies
5.4 Tissue-Engineering
5.5 Cell Therapies
5.6 Other Products

6 Global Regenerative Medicine Market, By Material
6.1 Introduction
6.2 Genetically Engineered Material
6.2.1 Transgenics
6.2.2 Genetically Manipulated Cell
6.2.3 Gene-Activated Matrices
6.2.4 Neural Stem Cell
6.2.5 Three-Dimensional Polymer Technology
6.2.6 Fibroblast
6.3 Synthetic material
6.3.1 Artificial vascular graft material
6.3.2 Hydrogel material
6.3.3 Scaffold
6.4 Biologically derived material
6.4.1 Xenogeneic material
6.4.2 Collagen
6.5 Pharmaceutical
6.5.1 Biologic

7 Global Regenerative Medicine Market, By Application
7.1 Introduction
7.2 Oncology
7.3 Wound Care
7.4 Cardiovascular
7.5 Musculoskeletal
7.6 Ophthalmology
7.7 Other Applications

8 Global Regenerative Medicine Market, By End User
8.1 Introduction
8.2 Government & Academic Research Institutes
8.3 Hospitals & Clinics
8.4 Commercial Industries

9 Global Regenerative Medicine Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa

10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling
11.1 Smith & Nephew plc
11.2 Shenzhen SibionoGeneTech Co., Ltd.
11.3 AstraZeneca
11.4 Aspect Biosystems
11.5 Integra LifeSciences Corporation
11.6 Novartis AG
11.7 Medtronic plc
11.8 Amgen, Inc.
11.9 MiMedx Group
11.10 Baxter
11.11 Eli Lilly & Co.
11.12 Mesoblast Ltd.
11.13 Bayer AG
11.14 Corestem, Inc.
11.15 Bluebird Bio, Inc.
11.16 Regrow Biosciences Pvt. Ltd.

List of Tables
1 Global Regenerative Medicine Market Outlook, By Region (2020-2028) ($MN)
2 Global Regenerative Medicine Market Outlook, By Product (2020-2028) ($MN)
3 Global Regenerative Medicine Market Outlook, By Progenitor and Stem Cell Therapies (2020-2028) ($MN)
4 Global Regenerative Medicine Market Outlook, By Gene Therapies (2020-2028) ($MN)
5 Global Regenerative Medicine Market Outlook, By Tissue-Engineering (2020-2028) ($MN)
6 Global Regenerative Medicine Market Outlook, By Cell Therapies (2020-2028) ($MN)
7 Global Regenerative Medicine Market Outlook, By Other Products (2020-2028) ($MN)
8 Global Regenerative Medicine Market Outlook, By Material (2020-2028) ($MN)
9 Global Regenerative Medicine Market Outlook, By Genetically Engineered Material (2020-2028) ($MN)
10 Global Regenerative Medicine Market Outlook, By Transgenics (2020-2028) ($MN)
11 Global Regenerative Medicine Market Outlook, By Genetically Manipulated Cell (2020-2028) ($MN)
12 Global Regenerative Medicine Market Outlook, By Gene-Activated Matrices (2020-2028) ($MN)
13 Global Regenerative Medicine Market Outlook, By Neural Stem Cell (2020-2028) ($MN)
14 Global Regenerative Medicine Market Outlook, By Three-Dimensional Polymer Technology (2020-2028) ($MN)
15 Global Regenerative Medicine Market Outlook, By Fibroblast (2020-2028) ($MN)
16 Global Regenerative Medicine Market Outlook, By Synthetic material (2020-2028) ($MN)
17 Global Regenerative Medicine Market Outlook, By Artificial vascular graft material (2020-2028) ($MN)
18 Global Regenerative Medicine Market Outlook, By Hydrogel material (2020-2028) ($MN)
19 Global Regenerative Medicine Market Outlook, By Scaffold (2020-2028) ($MN)
20 Global Regenerative Medicine Market Outlook, By Biologically derived material (2020-2028) ($MN)
21 Global Regenerative Medicine Market Outlook, By Xenogeneic material (2020-2028) ($MN)
22 Global Regenerative Medicine Market Outlook, By Collagen (2020-2028) ($MN)
23 Global Regenerative Medicine Market Outlook, By Pharmaceutical (2020-2028) ($MN)
24 Global Regenerative Medicine Market Outlook, By Biologic (2020-2028) ($MN)
25 Global Regenerative Medicine Market Outlook, By Application (2020-2028) ($MN)
26 Global Regenerative Medicine Market Outlook, By Oncology (2020-2028) ($MN)
27 Global Regenerative Medicine Market Outlook, By Wound Care (2020-2028) ($MN)
28 Global Regenerative Medicine Market Outlook, By Cardiovascular (2020-2028) ($MN)
29 Global Regenerative Medicine Market Outlook, By Musculoskeletal (2020-2028) ($MN)
30 Global Regenerative Medicine Market Outlook, By Ophthalmology (2020-2028) ($MN)
31 Global Regenerative Medicine Market Outlook, By Other Applications (2020-2028) ($MN)
32 Global Regenerative Medicine Market Outlook, By End User (2020-2028) ($MN)
33 Global Regenerative Medicine Market Outlook, By Government & Academic Research Institutes (2020-2028) ($MN)
34 Global Regenerative Medicine Market Outlook, By Hospitals & Clinics (2020-2028) ($MN)
35 Global Regenerative Medicine Market Outlook, By Commercial Industries (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

List of Figures

RESEARCH METHODOLOGY


Research Methodology

We at Stratistics opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.

Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.

Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.

Data Mining

The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.

Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.

Data Analysis

From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:

  • Product Lifecycle Analysis
  • Competitor analysis
  • Risk analysis
  • Porters Analysis
  • PESTEL Analysis
  • SWOT Analysis

The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.


Data Validation

The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.

We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.

The data validation involves the primary research from the industry experts belonging to:

  • Leading Companies
  • Suppliers & Distributors
  • Manufacturers
  • Consumers
  • Industry/Strategic Consultants

Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.


For more details about research methodology, kindly write to us at info@strategymrc.com

Frequently Asked Questions

In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.

Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.

All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

We have 3 different licensing options available in electronic format.

  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.

All our reports are typically be emailed to you as an attachment.

To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.

We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

Request Customization

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials